Ofatumumab
- Generic Name
- Ofatumumab
- Brand Names
- Arzerra, Kesimpta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 679818-59-8
- Unique Ingredient Identifier
- M95KG522R0
- Background
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and...
- Indication
Ofatumumab is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
...
- Associated Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL) - Refractory, Clinically Isolated Syndrome (CIS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS), Progressive Chronic Lymphocytic Leukaemia (CLL), Recurrent Chronic Lymphocytic Leukaemia (CLL)
- Associated Therapies
- -
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2016-02-24
- Target Recruit Count
- 64
- Registration Number
- NCT01195766
- Locations
- 🇪🇸
Hospital Rio Hortega, Valladolid, Spain
🇪🇸Hospital Carlos Haya, Malaga, Spain
🇪🇸Hospital Sant Pau, Barcelona, Spain
Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years
- Conditions
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 120
- Registration Number
- NCT01195714
- Locations
- 🇧🇪
Ch Hutois, Huy, Belgium
🇧🇪Clinique Saint Pierre, Ottignies, Belgium
🇧🇪Universite Catholique de Louvain Mont Godinne, Yvoir, Belgium
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
- Conditions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 28
- Registration Number
- NCT01187303
- Locations
- 🇩🇪
1st Department of Medicine, Cologne University Hospital, Cologne, Germany
Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 43
- Registration Number
- NCT01171378
- Locations
- 🇬🇧
St Bartholomew's Hospital, London, United Kingdom
🇬🇧Kings College Hospital, London, United Kingdom
🇬🇧Churchill Hospital, Oxford, United Kingdom
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
- Conditions
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 21
- Registration Number
- NCT01123356
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Greenville Hospital System, Greenville, South Carolina, United States
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT01113632
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸South Carolina Oncology Associates, Columbia, South Carolina, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 50
- Registration Number
- NCT01108341
- Locations
- 🇺🇸
Florida Cancer Institute - New Hope, New Port Richey, Florida, United States
🇺🇸Dublin Hematology Oncology Care P.C., Dublin, Georgia, United States
🇺🇸Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT01088048
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Oncology Specialists, S.C.
- Target Recruit Count
- 11
- Registration Number
- NCT01078922
- Locations
- 🇺🇸
Oncology Specialists, S.C., Park Ridge, Illinois, United States
🇺🇸Oncology Specialists, S.C, Niles, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 346
- Registration Number
- NCT01077518
- Locations
- 🇬🇧
Novartis Investigative Site, Uxbridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.